Cas12a/Guide RNA-Based Platform for Rapidly and Accurately Detecting blaKPC Gene in Carbapenem-Resistant Enterobacterales
Keke Li,Yaozhou Wu,Meng Liu,Junwen Yan,Lianhua Wei
DOI: https://doi.org/10.2147/idr.s462088
2024-06-20
Infection and Drug Resistance
Abstract:Keke Li, 1, &ast Yaozhou Wu, 1, 2, &ast Meng Liu, 1 Junwen Yan, 1 Lianhua Wei 1 1 Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, 730000, People's Republic of China; 2 First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lianhua Wei; Junwen Yan, Department of Clinical Laboratory, Gansu Provincial Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou, 730000, People's Republic of China, Email ; Purpose: Accurate detection and identification of pathogens and their associated resistance mechanisms are essential prerequisites for implementing precision medicine in the management of Carbapenem-resistant Enterobacterales (CRE). Among the various resistance mechanisms, the production of KPC carbapenemase is the most prevalent worldwide. Consequently, this study aims to develop a convenient and precise nucleic acid detection platform specifically for the bla KPC gene. Methods: The initial phase of our research methodology involved developing a CRISPR/Cas12a detection framework, which was achieved by designing highly specific single-guide RNAs (sgRNAs) targeting the bla KPC gene. To enhance the sensitivity of this system, we incorporated three distinct amplification techniques—polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA)—into the CRISPR/Cas12a framework. Subsequently, we conducted a comparative analysis of the sensitivity and specificity of these three amplification methods when used in combination with the CRISPR/Cas12a system. Additionally, we assessed the clinical applicability of the methodologies by evaluating fluorescence readouts from 80 different clinical isolates. Furthermore, we employed lateral flow assay technology to provide a visual representation of the results, facilitating point-of-care testing. Results: Following a comparative analysis of the sensitivity and specificity of the three methods, we identified the RPA-Cas12a approach as the optimal detection technique. Our findings demonstrated that the limit of detection (LoD) of the RPA-Cas12a platform was 1 aM (~1 copy/μL) for plasmid DNA and 5 × 103 fg/μL for genomic DNA. Furthermore, both the sensitivity and specificity of the platform achieved 100% upon validation with 80 clinical isolates. Conclusion: These findings suggest that the developed RPA-Cas12a platform represents a promising tool for the cost-effective, convenient, and accurate detection of the bla KPC gene. Keywords: Klebsiella pneumoniae carbapenemase, CRISPR-Cas12a, isothermal amplification, polymerase chain reaction, loop-mediated isothermal amplification, recombinase polymerase amplification, lateral flow strips Carbapenem-resistant Enterobacterales (CRE), defined as in vitro resistance to at least one carbapenem, was once considered the last-resort antibiotic against multidrug-resistant gram-negative pathogens. 1 In February 2017, as per the mandate from the World Health Organization (WHO), the position held by CRE is of utmost precedence (critical priority) in the sphere of novel and effective antibiotics development. 2 In the past decade, the incidence and prevalence of CRE were constantly high in the United States, Europe, the Middle East, and China. 3–6 Data from the China Antimicrobial Surveillance Network (CHINET, www.chinets.com ) revealed a significant increase in the resistance rates of Klebsiella pneumoniae to imipenem and meropenem, rising from 3.0% and 2.9% in 2005 to 26% and 27.5% in 2022, respectively. In Europe, the prevalence of carbapenem-resistant Klebsiella pneumoniae was approximately 60% in Greece and 40% in Italy. 4,5 According to the Centers for Disease Control and Prevention (CDC), approximately 13,100 cases of CRE occurred in the United States in 2019. 3 The carbapenem resistance of CRE is conferred by an increase in efflux pumps or a decrease in membrane permeability, alterations to the penicillin-binding protein, and the production of carbapenemase. 7,8 Reportedly, approximately 85% of CRE resistance mediates via the production of carbapenemases worldwide. 9 Between 2016 and 2018, pooled analyses from 36 hospitals across 24 provinces and cities in China demonstrated that the most prevalent carbapenemase among Klebsiella pneumoniae in adult patients was Klebsiella pneumoniae carbapenemase-2 (KPC-2), accounting for 64.6% (457/709) of cases. 6 Likewise, the production -Abstract Truncated-
pharmacology & pharmacy,infectious diseases